VKTX - NASDAQ

Viking Therapeutics, Inc.

VKTX·NASDAQ

$29.33

+0.037%

HealthcareBiotechnology

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$3.41B

EPS-3.1900

P/E Ratio-9.19

Earnings Date07/29/2026

715.73M

Assets

-21%

3Y+325.0%

5Y+179.0%

10Y+4824.0%

76.67M

Total Liabilities

173%

3Y+230.0%

5Y+531.0%

10Y+1081.0%

639.06M

Total Equity

-27%

3Y+340.0%

5Y+162.0%

10Y+7846.0%

Viking Therapeutics, Inc. Funding & Solvency Profile

VKTX · NASDAQ

Current Assets

Cash & Cash Equivalents165.81M

Net Receivables0.00

Inventory0.00

Other Current Assets9.86M

Total Current Assets716 M

Non-Current Assets

Property, Plant & Equipment85.00K

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets46.00K

Total Non-Current Assets131 K

Total Assets

715.73M

Financial Health Analysis

Current Ratio

9.33x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.12x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

639 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

100% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Viking Therapeutics, Inc. Balance Sheet

VKTX • NASDAQ

Viking Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	165.8M	26.7M	55.5M	36.6M	26.4M	29.1M	8.4M	24.8M	9M	3.1M	768.6K	755.9K	179.6K	0.0
Short-Term Investments	539.9M	875.9M	306.6M	118.9M	175.7M	219.3M	267.3M	276.7M	11.6M	10.1M	13.3M	0.0	0.0	0.0
Cash & Short-Term Investments	705.7M	902.6M	362.1M	155.5M	202.1M	248.4M	275.6M	301.5M	20.6M	13.2M	14.1M	755.9K	179.6K	0.0
Prepaids	0.0	3.5M	2.6M	3.4M	619K	442K	405K	278K	886.9K	824.3K	1.1M	17.8K	0.0	0.0
Other Current Assets	9.9M	1.1M	2.5M	8.1M	7.8M	7.3M	7.5M	0.0	389K	824.3K	0.0	0.0	0.0	0.0
Total Current Assets	715.6M	907.2M	367.2M	167M	210.5M	256.1M	283.5M	302.1M	21.9M	14M	15.2M	773.7K	179.6K	0.0
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	85K	1M	1.1M	1.4M	25K	321K	598K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	46K	102K	139K	71K	109K	78K	157K	179K	269.6K	560.9K	237.5K	2.3M	775.0	0.0
Total Non-Current Assets	131K	1.1M	1.3M	1.5M	134K	399K	755K	179K	269.6K	560.9K	237.5K	2.3M	775.0	0.0
Total Assets	715.7M	908.3M	368.5M	168.5M	210.7M	256.5M	284.3M	302.3M	22.1M	14.5M	15.4M	3M	180.4K	0.0
LIABILITIES
CURRENT LIABILITIES
Total Payables	53.3M	9.8M	7.5M	8.5M	1.4M	4M	2.4M	959K	1.5M	1.2M	592.4K	1.8M	73.4K	54K
Accounts Payable	53.3M	9.8M	7.5M	8.5M	1.4M	4M	2.4M	959K	1.5M	1.2M	592.4K	1.8M	73.4K	54K
Accrued Expenses	23.3M	17.1M	11.3M	13.1M	7.3M	7.8M	4M	3.6M	2.3M	1.3M	1.4M	20.3M	7.2K	350.0
Short Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5M	3.3M	0.0	304.3K	46.9K	0.0
Capital Lease Obligations (Current)	137K	489K	324K	304K	29K	330K	302K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3M	1.3M	0.0	20.3M	0.0	0.0
Other Current Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4M	731K	0.0	58.7K	0.0	0.0
Total Current Liabilities	76.7M	27.4M	19.1M	21.9M	8.8M	12.1M	6.8M	4.6M	8.7M	6.5M	2M	22.5M	127.5K	54.4K
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2M	1.3M	231.9K	42.8K
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12K	0.0	16.3K	2.6M	1.4M	71.7K	8.3K
Total Non-Current Liabilities	0.0	630K	936K	1.3M	0.0	29K	360K	12K	5M	16.3K	4.7M	2.7M	303.5K	51K
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-5M	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations	137K	1.1M	1.3M	1.6M	29K	359K	662K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	76.7M	28M	20.1M	23.2M	8.8M	12.2M	7.1M	4.6M	8.7M	6.5M	6.7M	25.2M	431K	105.4K
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	-6.8M	-6.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Common Stock	1K	1K	1K	1K	1K	1K	1K	1K	358.0	208.0	97.0	60.0	52.0	50.0
Additional Paid-In Capital	1.5B	1.4B	733.5M	445.3M	425.6M	412.6M	405.8M	401.1M	94.3M	68.3M	54.3M	12.9K	11.1K	5.6K
Retained Earnings	-847.5M	-487.9M	-377.9M	-292M	-223.2M	-168.2M	-128.7M	-102.9M	-80.9M	-60.3M	-45.5M	-22.1M	-257.3K	-111K
Accumulated Other Comprehensive Income/Loss	378K	-788K	-389K	-1.1M	-549K	-54K	12K	-423K	-19.8K	-6.9K	-7.4K	0.0	-4.5K	0.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	49.0
Total Stockholders' Equity	639.1M	880.3M	348.4M	145.3M	201.9M	244.3M	277.1M	297.8M	13.5M	8M	8.7M	-22.1M	-250.6K	-105.4K
Total Equity	639.1M	880.3M	348.4M	145.3M	201.9M	244.3M	277.1M	297.8M	13.5M	8M	8.7M	-22.1M	-250.6K	-105.4K
SUMMARY
Total Liabilities & Equity	715.7M	908.3M	368.5M	168.5M	210.7M	256.5M	284.3M	302.3M	22.1M	14.5M	15.4M	3M	180.4K	0.0
Total Investments	539.9M	875.9M	306.6M	118.9M	175.7M	219.3M	267.3M	276.7M	11.6M	10.1M	13.3M	0.0	0.0	0.0
Total Debt	137K	1.1M	1.3M	1.6M	29K	359K	662K	0.0	3.5M	3.3M	2.2M	1.6M	278.7K	42.8K
Net Debt	-165.7M	-25.6M	-54.3M	-35.1M	-26.3M	-28.8M	-7.7M	-24.8M	-5.5M	194.1K	1.4M	812.5K	99.1K	42.8K
Shares Outstanding	113,029,102	113,029,102	113,029,102	113,029,102	113,029,102	113,029,102	113,029,102	113,029,102	113,029,102	113,029,102	113,029,102	113,029,102	113,029,102	113,029,102

SEC Filings

VKTX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 26, 2026	May 19, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	April 30, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 29, 2026	April 29, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 01, 2026	May 19, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 11, 2026	February 11, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 11, 2026	December 31, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	October 23, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 22, 2025	October 22, 2025	2025	View Filing
8-K 8-K 2025 N/A	August 19, 2025	August 19, 2025	2025	View Filing
8-K 8-K 2025 N/A	July 23, 2025	July 23, 2025	2025	View Filing

Showing 1 to 10 of 183 filings

Related Guides

Blog Categories

Continue your VKTX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.